Please use this identifier to cite or link to this item:
Title: Baseline hepatitis C virus resistance-associated substitutions present at frequencies lower than 15% may be clinically significant
Author: Perales, Celia
Chen, Qian
Soria, Maria Eugenia
Gregori, Josep
Garcia Cehic, Damir
Nieto Aponte, Leonardo
Castells, Lluis
Imaz, Arkaitz
Llorens Revull, Meritxell
Domingo, Esteban
Buti, Maria
Esteban, Juan Ignacio
Rodríguez Frias, Francisco
Quer, Josep
Keywords: Hepatitis C
Medicaments antivírics
Hepatitis C
Antiviral agents
Issue Date: 1-Jan-2018
Publisher: Dove Medical Press Ltd.
Abstract: Background: Controversy is ongoing about whether a minority mutant present at frequencies below 15% may be clinically relevant and should be considered to guide treatment. Methods: Resistance-associated substitution (RAS) studies were performed in patients before and at failure of antiviral treatments using Next-generation hepatitis C virus (HCV) sequencing (NGS). Results: We have found two patients with genotype 1a infection having RAS in 3.5%-7.1% of the viral population at baseline that were selected during ledipasvir + sofosbuvir treatment. Coselection of RAS located in a region not directly affected by the antiviral treatment also occurred. This observation calls into question, the recommendations to guide RAS-based direct-acting antiviral (DAA) treatment only when RAS are present in > 15% of the sequences generated. Conclusion: Our results suggests that RAS study should include all three HCV DAA target proteins and minority mutants should be considered as clinically relevant.
Note: Reproducció del document publicat a:
It is part of: Infection and Drug Resistance, 2018, vol. 11, p. 2207-2210
Related resource:
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
PeralesC.pdf135.88 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons